Expertise in
2
conditions

Dr. John Stoukides

Palliative Medicine
Rhode Island Mood And Memory Research Institute
1018 Waterman Ave, 
East Providence, RI 
Expertise in
2
conditions
Rhode Island Mood And Memory Research Institute
1018 Waterman Ave, 
East Providence, RI 

Overview

John Stoukides is a primary care provider, practicing in Palliative Medicine in East Providence, Rhode Island. Dr. Stoukides is highly rated in 2 conditions, according to our data. His top areas of expertise are Alzheimer's Disease, Dementia, Sepsis, Hip Replacement, and Colonoscopy.

His clinical research consists of participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Palliative Medicine

Licenses

Geriatric Medicine in RI

Hospital Affiliations

Roger Williams Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Rhode Island Mood and Memory Research Institute
1018 Waterman Ave, East Providence, RI 02914

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Drug
Study Drug: LY3372689
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Enrollment Status: Completed
Publish Date: October 24, 2018
Intervention Type: Drug
View 11 Less Clinical Trials
Similar Doctors
Expertise in
14
conditions
Dr. John Flynn
Palliative Medicine
Expertise in
14
conditions
Dr. John Flynn
Palliative Medicine

Office

2014 Washington St, 
Newton Lower Falls, MA 
 (35.4 miles away)
617-243-6345
Languages Spoken:
English
See accepted insurances

John Flynn is a primary care provider, practicing in Palliative Medicine in Newton Lower Falls, Massachusetts. Dr. Flynn is highly rated in 14 conditions, according to our data. His top areas of expertise are Scoliosis, Adolescent Idiopathic Scoliosis, Kyphosis, Spinal Fusion, and Osteotomy.

Expertise in
29
conditions
Dr. Joseph Alessandro
Palliative Medicine
Expertise in
29
conditions
Dr. Joseph Alessandro
Palliative Medicine

Joseph Alessandro

111 Westcott Rd, 
Danielson, CT 
 (22.7 miles away)
860-774-9540
Languages Spoken:
English
See accepted insurances

Joseph Alessandro is a Palliative Medicine provider in Danielson, Connecticut. Dr. Alessandro is highly rated in 29 conditions, according to our data. His top areas of expertise are Alzheimer's Disease, Dementia, Vascular Dementia, and Liver Failure.

Expertise in
2
conditions
Dr. Richard Goldstein
Palliative Medicine
Expertise in
2
conditions
Dr. Richard Goldstein
Palliative Medicine

Boston Children's Hospital

300 Longwood Ave, 
Boston, MA 
 (38.5 miles away)
617-632-3270
Languages Spoken:
English
See accepted insurances

Richard Goldstein is a Palliative Medicine provider in Boston, Massachusetts. Dr. Goldstein is highly rated in 2 conditions, according to our data. His top areas of expertise are Sudden Infant Death Syndrome (SIDS), Epilepsy in Children, Traumatic Brain Injury, and Genetic Epilepsy with Febrile Seizures Plus (GEFS+).

Frequently Asked Questions about Dr. John Stoukides

How do I make an appointment with Dr. John Stoukides?

You can book an appointment with Dr. John Stoukides by calling their office at 401-231-0450. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John Stoukides a top-rated expert for Alzheimer's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John Stoukides is classified as an Distinguished expert for Alzheimer's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John Stoukides specialize in?

While Dr. John Stoukides is a Palliative Medicine, they have specific expertise in Alzheimer's Disease, Dementia, and Sepsis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Palliative Medicine.

Does Dr. John Stoukides accept my insurance?

Dr. John Stoukides accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 401-231-0450 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stoukides's expertise for a condition
ConditionClose
      View All 69 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile